Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
New Year's Insider Buying Focuses on Biotechs
12:59pm, Wednesday, 17'th Jan 2024
As the year got underway, biotechs were in focus among the notable insider purchases.
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
07:30am, Friday, 05'th Jan 2024
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
10:46pm, Thursday, 04'th Jan 2024
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics surpasses $1B valuation in strong start to 2024
12:54pm, Thursday, 04'th Jan 2024
Dyne Therapeutics is off to a strong start in 2024 with positive trial data from its Duchenne muscular dystrophy (DMD) program. The company released positive initial proof-of-concept data for its two
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
04:25pm, Wednesday, 03'rd Jan 2024
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today?
08:19am, Wednesday, 03'rd Jan 2024
Dyne Therapeutics (NASDAQ: DYN ) stock is taking off on Wednesday after the muscle disease company announced positive clinical trial data. According to a press release from Dyne Therapeutics, its ACH
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
08:19am, Wednesday, 03'rd Jan 2024
Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition
06:59pm, Monday, 13'th Nov 2023
After dropping to 52-week lows, the markets have been rallying lately. That has traders and investors scrambling for cheap stocks under $20 to buy.
Dyne Therapeutics to Present at October Investor Conferences
07:30am, Thursday, 28'th Sep 2023
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Why Shares of Dyne Therapeutics Fell This Week
01:52pm, Friday, 15'th Sep 2023
Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders.
Dyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early Stages
05:25am, Sunday, 10'th Sep 2023
Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Their lead candidate, DYNE-101, is
Dyne Therapeutics to Present at Jefferies Healthcare Conference
07:30am, Thursday, 01'st Jun 2023
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
